ArticleHuman cell2025
Antitumoral effect of Nitraria retusa bioactive compounds on two glioblastoma cell lines.
Article in Human cell, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of this research was to investigate the effects of proven antioxidant compounds identified in Nitraria retusa leaf extracts (Nr-extracts) on glioblastoma (GBM) cells. The antioxidant capacity was evaluated in nonenzymatic, enzymatic, and cellular systems. The antitumoral effect was demonstrated first by studying the inhibition of glioblastoma cell growth, then by examining the inhibition of cell adhesion to various purified extracellular matrix (ECM) proteins, and finally by assessing the ability of Nr-extracts to abolish the invasion of collagen gel by human glioblastoma cell spheroids. The methanolic extract (Nr-MeOH), through its isorhamnetin and carbohydrate derivatives, showed the highest antioxidant capacity. The cytotoxicity study of Nr-extracts, in the absence and presence of TEMODAL (TPZ), revealed that the chloroform extract (Nr-Chl), through its β-sitosterol and in combination with TEMODAL, exerted a more significant apoptotic effect on glioblastoma cells than TEMODAL alone. However, only the Nr-Chl and Nr-MeOH extracts inhibited the attachment of U87 cells to fibronectin, vitronectin, and collagen I. In addition, Nr-MeOH more significantly reduced U87 cell invasion compared with Nr-Chl extract. In conclusion, flavonols and sterols demonstrated strong antitumoral and free radical-scavenging activities, suggesting that a potentially synergistic therapeutic approach for glioma can be developed.
Indexed as
Identifiers
41420680What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.